Proto-oncogene protein c-bcl-2 inhibitors - Pipeline Insight, 2024

This “Proto-oncogene protein c-bcl-2 inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 16+ companies and 16+ pipeline drugs in Proto-oncogene protein c-bcl-2 inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Proto-oncogene protein c-bcl-2 inhibitors Understanding

Proto-oncogene protein c-bcl-2 inhibitors: Overview

BCL-2 was the first anti-death gene discovered, a milestone with far reaching implications for tumor biology. Multiple members of the human Bcl-2 family of apoptosis-regulating proteins have been identified, including six antiapoptotic, three structurally similar proapoptotic proteins and several structurally diverse proapoptotic interacting proteins that operate as upstream agonists or antagonists. Membrane proteins encoded by the BCL-2 GENES and serving as potent inhibitors of cell death by APOPTOSIS. The proteins are found on mitochondrial, microsomal, and NUCLEAR MEMBRANE sites within many cell types. Overexpression of bcl-2 proteins, due to a translocation of the gene, is associated with follicular lymphoma. Development of small molecule inhibitors (SMI) specific for antiapoptotic Bcl-2 proteins is a novel approach in a way that these antagonists are aimed to interfere with specific protein-protein interactions unlike conventional chemo-/radiotherapies.

Proto-oncogene protein c-bcl-2 inhibitors - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Proto-oncogene protein c-bcl-2 inhibitors pipeline landscape is provided which includes the disease overview and Proto-oncogene protein c-bcl-2 inhibitors treatment guidelines. The assessment part of the report embraces, in depth Proto-oncogene protein c-bcl-2 inhibitors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Proto-oncogene protein c-bcl-2 inhibitors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Proto-oncogene protein c-bcl-2 inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve Proto-oncogene protein c-bcl-2 inhibitors.

Proto-oncogene protein c-bcl-2 inhibitors Emerging Drugs Chapters

This segment of the Proto-oncogene protein c-bcl-2 inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Proto-oncogene protein c-bcl-2 inhibitors Emerging Drugs

Navitoclax: AbbVieNavitoclax (ABT-263) is an orally active dual inhibitor of the antiapoptotic proteins, BCL-XL and BCL-2. Navitoclax is in clinical development for myelofibrosis in combination with ruxolitinib, for myeloproliferative neoplasms with or without ruxolitinib. Navitoclax (ABT-263) is an unapproved investigational drug under clinical development. Safety and efficacy have not been established. It is currently being evaluated in Phase III stage of development for the treatment of myelofibrosis.

Lisaftoclax: Ascentage PharmaLisaftoclax is a novel, orally administered small-molecule Bcl-2-selective inhibitor being developed by Ascentage Pharma. Lisaftoclax is designed to treat hematologic malignancies and solid tumors by selectively blocking antiapoptotic protein Bcl-2 to restore the normal apoptosis process in cancer cells. Lisaftoclax is the first China-developed Bcl-2 inhibitor entering clinical development in China. Previously, lisaftoclax had received clearances and approvals for multiple Phase Ib/II clinical studies in China, Australia, the US, and Europe, and is currently being developed in a range of hematologic malignancies globally. As a single agent, lisaftoclax has potent antitumor activity in Bcl-2-dependent tumor cell lines, and has shown broad antitumor effects when combined with other antitumor therapies.

Proto-oncogene protein c-bcl-2 inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Proto-oncogene protein c-bcl-2 inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Proto-oncogene protein c-bcl-2 inhibitors

There are approx. 16+ key companies which are developing the therapies for Proto-oncogene protein c-bcl-2 inhibitors. The companies which have their Proto-oncogene protein c-bcl-2 inhibitors drug candidates in the most advanced stage, i.e. phase III include AbbVie.

Phases

This report covers around 16+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Proto-oncogene protein c-bcl-2 inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Subcutaneous
• Intravenous
• Intramuscular
• Molecule Type

Products have been categorized under various Molecule types such as

• Peptides
• Polymer
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Proto-oncogene protein c-bcl-2 inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Proto-oncogene protein c-bcl-2 inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Proto-oncogene protein c-bcl-2 inhibitors drugs.

Proto-oncogene protein c-bcl-2 inhibitors Report Insights

• Proto-oncogene protein c-bcl-2 inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Proto-oncogene protein c-bcl-2 inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Proto-oncogene protein c-bcl-2 inhibitors drugs?
• How many Proto-oncogene protein c-bcl-2 inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Proto-oncogene protein c-bcl-2 inhibitors?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Proto-oncogene protein c-bcl-2 inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Proto-oncogene protein c-bcl-2 inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

This product will be delivered within 1-3 business days.